Unlock stock picks and a broker-level newsfeed that powers Wall Street.

IOB - Delayed Quote EUR

Faes Farma, S.A. (0K9H.IL)

4.1275
+0.0050
+(0.12%)
At close: April 24 at 5:09:26 PM GMT+1
Loading Chart for 0K9H.IL
  • Previous Close 4.1225
  • Open 0.0000
  • Bid 4.0250 x --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 4.1450
  • Volume 43,696
  • Avg. Volume 16,859
  • Market Cap (intraday) 1.397B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) 14.74
  • EPS (TTM) 0.2800
  • Earnings Date Apr 30, 2025
  • Forward Dividend & Yield 0.07 (2.38%)
  • Ex-Dividend Date Apr 12, 2023
  • 1y Target Est --

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it manufactures and sells animal nutrition and health products. It also exports its products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

faesfarma.com

1,764

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0K9H.IL

View More

Performance Overview: 0K9H.IL

Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .

YTD Return

0K9H.IL
20.88%
IBEX 35... (^IBEX)
14.24%

1-Year Return

0K9H.IL
31.58%
IBEX 35... (^IBEX)
19.51%

3-Year Return

0K9H.IL
19.06%
IBEX 35... (^IBEX)
52.33%

5-Year Return

0K9H.IL
28.06%
IBEX 35... (^IBEX)
99.27%

Compare To: 0K9H.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0K9H.IL

View More

Valuation Measures

Annual
As of 4/23/2025
  • Market Cap

    1.28B

  • Enterprise Value

    1.23B

  • Trailing P/E

    11.58

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.61

  • Price/Book (mrq)

    1.77

  • Enterprise Value/Revenue

    2.50

  • Enterprise Value/EBITDA

    9.61

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.13%

  • Return on Assets (ttm)

    8.90%

  • Return on Equity (ttm)

    14.58%

  • Revenue (ttm)

    468.68M

  • Net Income Avi to Common (ttm)

    89.64M

  • Diluted EPS (ttm)

    0.2800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    46.52M

  • Total Debt/Equity (mrq)

    2.34%

  • Levered Free Cash Flow (ttm)

    -36.55M

Research Analysis: 0K9H.IL

View More

Company Insights: 0K9H.IL

Research Reports: 0K9H.IL

View More

People Also Watch